Clinical Research

San Diego – September 22, 2026 -- BRIJ Medical reported zero documented cases of wound dehiscence, infection, allergic dermatitis, adhesive-related skin injury or wound-related reoperation across a 100-case retrospective study of its Brijjit Force-Modulating Tissue Bridges in sports medicine incision management.

Single-surgeon study spans three years of orthopedic procedures

The study, published in the Journal of Orthopaedic Experience & Innovation (Volume 7, Issue 2), evaluated 100 consecutive outpatient sports medicine procedures performed by a single surgeon, John A. Grotting, MD, between January 2023 and December 2025. Cases spanned ACL, knee, shoulder, elbow and ankle procedures, with co-author Ege Karadag.

New York – September 22, 2026 -- NYU Langone Health's Perlmutter Cancer Center has appointed Rutika Mehta, MD, MPH, as director of upper GI medical oncology, expanding its clinical and research programs for esophageal and stomach cancers.

Mehta brings a clinical trials portfolio built at two prior academic centers

Mehta joins from Weill Cornell Medicine, where she established an Upper GI Working Group to advance clinical and research collaboration. She previously helped build the Upper GI Malignancies Program at Moffitt Cancer Center in Tampa, Florida, developing a clinical trials portfolio that gave patients access to new treatment options.

Gainesville, Fla. – September 21, 2026 -- Advita Ortho has launched Axis, a clinical research platform drawing on more than 20 years of shoulder arthroplasty data covering over 25,000 patients across 45 clinical sites worldwide.

Two decades of data produce 250 peer-reviewed studies

The dataset behind Axis has generated more than 250 peer-reviewed publications and dozens of first-to-market product innovations, according to the company. Chris Roche, Advita Senior Vice President, Extremities, said the initiative distills findings from the company's highest-impact studies into a format designed for practicing surgeons.

Beijing – September 21, 2026 -- T-MAXIMUM Pharmaceutical reported that two of three evaluable patients with refractory brain metastases from lung cancer achieved partial responses with roughly 80% tumor shrinkage after treatment with its allogeneic B7-H3-targeted CAR-T therapy, MT027, according to early data presented at the IASLC World Conference on Lung Cancer (WCLC 2026) in Seoul.

Two of three evaluable patients hit 80% tumor shrinkage in dose-escalation trial

In the prospective, investigator-initiated trial (ChiCTR2500107346), five patients with heavily pretreated, guideline-exhausted brain metastases completed treatment. Of the three with measurable disease, two achieved partial responses and one achieved stable disease. As of the company's September 2026 follow-up, the two responders have survived more than 11 and 13 months, respectively, since their first MT027 dose, and all three evaluable patients remain alive.

Las Vegas – September 21, 2026 -- Concept Medical's MagicTouch sirolimus-coated balloon will face fresh scrutiny at VIVA 2026 as researchers unveil new subgroup data from the SirPAD randomized trial covering 597 patients treated for femoropopliteal peripheral artery disease without tissue loss.

SirPAD enrolled 1,252 patients to compare drug-coated and uncoated balloon angioplasty

The academic, investigator-initiated trial randomized 1,252 patients with symptomatic infrainguinal peripheral artery disease to angioplasty using either the MagicTouch PTA sirolimus-coated balloon or an uncoated balloon. Primary results, published in the New England Journal of Medicine, showed the sirolimus-coated balloon arm was both non-inferior and superior to the uncoated balloon on major adverse limb events (MALE) at one year.

Atlanta and Los Angeles – September 21, 2026 -- StimCardio Medical reported that patients treated with non-invasive median nerve stimulation (MNS) after atrial fibrillation (AF) ablation showed 90.0% freedom from atrial arrhythmias at six months, compared with 80.8% for those receiving sham treatment, though the difference did not reach statistical significance. The randomized, double-blind, sham-controlled NeuroPulse pilot study was presented as late-breaking clinical science at HRX Live 2026 and simultaneously published in the peer-reviewed journal Heart Rhythm.

Post-blanking analysis finds statistically significant drop in arrhythmia events

In a sensitivity analysis conducted after the 60-day blanking period, patients receiving MNS recorded 12 recurrent atrial arrhythmia events versus 28 in the sham group, a statistically significant reduction (p=0.025). No MNS- or device-related serious adverse events were reported across the trial.

Plymouth Meeting, Pa. – September 18, 2026 -- The National Comprehensive Cancer Network (NCCN) Oncology Research Program has awarded funding for four quality improvement projects targeting metastatic prostate cancer (mPCA) care, backed by Pfizer Global Medical Grants (GMG).

Four institutions receive two-year grants to standardize mPCA treatment protocols

The selected projects, each set for completion within two years, will run at UT Southwestern Simmons Comprehensive Cancer Center, Georgetown University, Northwestern University's Robert H. Lurie Comprehensive Cancer Center, and Moffitt Cancer Center. Changchuan (Charles) Jiang, MD, at UT Southwestern will lead a biomarker action-loop initiative within a major U.S. safety-net cancer program. Paul Leger, MD, at Georgetown will implement multilevel interventions across the Medstar Health Network under the I-CARE PCA project.

Shanghai and Hong Kong – September 17, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) has published preclinical data showing that combining its CD73 inhibitor ATG-037 with selinexor suppressed tumor growth by 62% in a multiple myeloma mouse model, versus 31% for ATG-037 alone and 43% for selinexor alone. The peer-reviewed paper, developed with the Department of Hematology at Peking University Third Hospital, appears in Cancer Gene Therapy, an SCI journal under Springer Nature (DOI: 10.1038/s41417-026-01078-9).

Boston – September 17, 2026 -- PerZeption Inc. has secured a Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute to fund development of a new photostress recovery test for age-related macular degeneration (AMD), a condition affecting an estimated 20 million people in the United States.

NEI Funds Photostress Recovery Test for Earlier AMD Detection

The award backs the project "Efficient Achromatic and Chromatic Photostress Recovery Assessment for Age-related Macular Degeneration," which will be carried out in collaboration with researchers at the Brunson Center for Translational Vision Research at the University of California, Irvine. The work targets how quickly vision recovers after bright-light exposure, a marker of macular health that can reveal functional deficits before they show up on standard acuity tests.

Maidenhead, United Kingdom – September 17, 2026 -- CSL Seqirus has published pivotal Phase 3 results for its MF59-adjuvanted, cell-based, higher-dose quadrivalent influenza vaccine (aQIVc) in The Lancet Infectious Diseases, reporting superiority over an adjuvanted egg-based comparator across all four influenza strains and age groups tested in a 7,699-participant trial.

Trial enrolled nearly 7,700 adults aged 50 and older across eight countries

The randomised, observer-blind study recruited participants in Canada, Denmark, Estonia, Germany, Pakistan, the Philippines, the United Kingdom and the United States, comparing aQIVc against an MF59-adjuvanted egg-based quadrivalent vaccine and a recombinant quadrivalent vaccine. The vaccine met its primary objectives, showing non-inferiority versus the recombinant comparator for three of four strains in the 50-plus group and four of four strains in those aged 65 and above.